NCT05209074View on ClinicalTrials.gov

Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 8, 2022

Primary Completion Date

July 15, 2026

Study Completion Date

December 31, 2026

Conditions
Pancreatic Ductal AdenocarcinomaResectable Pancreatic Cancer
Interventions
DRUG

Ivosidenib

Ivosidenibflat dose (250mgor 500mg) daily on day 1 of a 14 day cycle.

DRUG

mFOLFIRINOX

mFOLFIRINOX on days 1-3 of a 14-day cycle. Surgical resection after up to ninety (90) days of treatment.

Trial Locations (1)

44106

University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Case Comprehensive Cancer Center

OTHER